Clintabs Tablets is a prescription broad-spectrum antibiotic used to treat bacterial infections of the skin, mouth and bones caused by certain types of bacteria. It may also be prescribed to treat certain protozoan infections, such as toxoplasmosis and babesiosis. It works by stopping bacteria from producing proteins that encourage their growth and reproduction, stopping the spread of infection and allowing the body's immune system to kill the bacteria
This orally-administered medication works by suppressing the reproduction and growth of bacteria.
Clintabs Tablets (brand of clindamycin hydrochloride) (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:
Oral: 2.5-15.0 mg/lb body weight every 12 hours.
Duration: Treatment with clindamycin hydrochloride products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.
Clintabs 25mg, administer 1-6 tablets every 12 hours for each 10 pounds of body weight.
Clintabs 75mg, administer 1-6 tablets every 12 hours for each 30 pounds of body weight.
Clintabs 150mg, administer 1-6 tablets every 12 hours for each 60 pounds of body weight.
Oral: 5.0-15.0 mg/kg body weight every 12 hours.
Duration: Treatment with clindamycin hydrochloride is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.
Clintabs 25mg, administer 2-6 tablets every 12 hours for each 10 pounds of body weight.
Clintabs 75mg, administer 2-6 tablets every 12 hours for each 30 pounds body weight.
Clintabs 150mg, administer 2-6 tablets every 12 hours for each 60 pounds of body weight.
Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.
Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.5 mg/lb/day) shown clindamycin hydrochloride capsules to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.
Safety in gestating bitches or breeding males has not been established.
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
Clintabs Tablets are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.
Keep out of reach of children. Not for human use.
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
The use of clindamycin hydrochloride occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of Clintabs Tablets should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see Contraindications).
Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.
Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.
Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, Clintabs Tablets should be used with caution in animals receiving such agents.
Safety in gestating bitches or breeding male dogs has not been established.
Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.
To report adverse reactions or a suspected adverse reaction, call 1-800-338-3659.
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Features of Clindamycin: